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Abstract. The biological mode of action of platencin, a potential lead molecule 
for a new class of antibiotics, is detailed. Furthermore, enantiopure syntheses of 
several platencin derivatives are described, of which the core structure can be 
accessed in two exceedingly simple steps from commercially available starting 
materials. Furthermore, the antibiotic properties of the derivatives was evaluated. 
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1 Introduction 
The emergence of resistant pathogens is a rapidly increasing concern to society 
and has been identified by the World Health Organization (WHO) as one of the 
three greatest threats to human health. According to the Infectious Diseases 
Society of America (IDSA), in 2005 more than 50% of the Staphylococcus 
aureus infections encountered in hospitalized patients involved methicillin 
resistant Staphylococcus aureus (MRSA). This bacterium alone is responsible 
for 19.000 deaths annually in the USA and has become a prime concern in 
hospitals. The recent call of the IDSA to develop ten new antibiotics by 2020 
further illustrates the pressing need for new classes of antibiotics. However, 
with only three new classes of antibacterial agents approved for clinical use 
since 1962 [1], the pharmaceutical industry lags far behind.Since the 1960's, 
fighting microbial resistance mainly relied on modification of existing 
antibiotics. However, because it becomes increasingly more difficult to 
manipulate existing antibiotics while retaining the activity, also in this area the 
pipeline is running dry. In 2009, only two new antibiotics entered the market; 
telavancin [2,3], a semi-synthetic derivative of vancomycin, and besifloxacin 
[2], a fourth-generation fluoroquinolone. More strikingly, in 2004, out of the 
506 drugs in late-stage clinical testing by the 15 largest pharmaceutical 
companies, only six were new antibacterials, which were all derivatives of 
known antibiotics [4]. One of the main reasons for the declining interest of the 
pharmaceutical industry in the development of new antibiotics is the inevitable 
paradox that although the rapidly emerging resistance calls for more antibiotics, 
a new antibiotic, to which no resistance exists, will preferably be held in reserve 
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until all other therapies fail. Ending up with a second-line therapeutic agent will 
certainly not appeal to the pharmaceutical industry when it costs $1,800 million 
on average and 10-15 years to bring a new drug to the market [5]. Additionally, 
chronic diseases, where drugs are prescribed for years or even lifelong, are 
financially more attractive than the treatment of infections, where medication is 
typically used for weeks. To steer clear of a health-care calamity, several 
incentives for the pharmaceutical industry to develop new antibiotics are 
investigated. These include patent extension for one of the company’s drugs, 
limiting liability for adverse effects and advanced purchase commitment from 
the government. Revision of clinical trial protocols to facilitate approval of new 
antibiotics by the US Food and Drug Administration (FDA) is also discussed, 
but has so far not led to major changes [6]. 
In this respect, the recent discovery of potent inhibitors of an essential and 
unexploited bacterial pathway by Merck is especially encouraging. Using 
antisense RNA silencing, researchers systematically screened 250.000 natural 
product extracts for inhibition of the fatty acid synthesis in bacteria to find two 
potent inhibitors of this pathway, platensimycin (1) [7] and platencin (2) (Figure 
1) [8]. Both compounds were recovered from soil extracts collected in South 
Africa and Spain, respectively, and showed potent broad-spectrum Gram-
positive antibacterial activity.  
 
 
Figure 1 Structures of (–)-platensimycin (1) and (–)-platencin (2). 
The bacterial type II fatty acid synthesis (FAS II) [9] differs significantly from 
the type I fatty acid synthesis (FAS I) [10] in animals and humans. Bacteria rely 
on several distinct enzymes for the production of essential fatty acids, but in 
humans the overall reaction is performed by one large dimeric enzyme which 
incorporates no less than seven different catalytic sites. Because the protein 
sequences and the active sites of the two types differ significantly, the type II 
fatty acid synthesis is considered an attractive target for the development of new 
antibiotics [11]. As detailed in Figure 2, the first committed step in the FAS II 
pathway is the carboxylation of acetyl-CoA which is carried out by acetyl-CoA 
carboxylase (ACC) [12]. This multi-subunit enzyme is encountered in different 
forms in virtually all living organisms including plants, where plant-ACC is the 
target of widely used herbicides. The recent discovery of several bacterial ACC 
inhibitors provided promising results for their use as antibiotics [13]. In the next 
 Synthesis and Biological Activity of Novel Platencin Derivatives 97 
 
step, FabD, a malonyl-CoA:ACP transacylase, catalyzes the transfer of a 
malonyl group from coenzyme A (CoA) to the acetyl carrier protein (ACP) 
[14]. This enzyme is present in excess and is not considered to play an essential 
role in fatty acid synthesis. Conversely, the subsequent condensation of 
malonyl-ACP with acetyl-CoA to form β-ketobutyryl-ACP, catalyzed by FabH, 
is a crucial initiating step in the fatty acid synthesis cycle. However, targeting 
this enzyme across a wide range of bacteria is challenging because of structural 
variations in the substrate binding site of FabH [15]. These architectural 
differences determine the fatty acid profile of an organism which causes e.g. 
Escherichia coli to produce predominantly straight-chain fatty acids and 
Streptomyces glaucescens to produce both straight and branched chain fatty 
acids. Nonetheless, several inhibitors of FabH have been reported of which 
platencin (2) is the most potent one (IC50 = 3.91 µg mL–1 in S. aureus), 
demonstrating the viability of FabH as an antibiotic target [8].  
In contrast to FabH, the next enzyme in the cycle is highly conserved and only a 
single isoform is known in bacteria. This enzyme, FabG, is a reductase which 
catalyzes the reduction of a β-ketoacyl intermediate by NADPH. Interestingly, 
FabG is the only enzyme in the catalytic cycle that undergoes a substantial 
conformational change upon binding of its cofactor which could offer additional 
opportunities for drug development [16]. However, this enzyme is not rate 
limiting in the catalytic cycle which possibly explains why the few reported 
inhibitors of FabG only show moderate antibiotic activity [17]. In the next step, 
the alcohol of the β-hydroxyacetyl-ACP complex is eliminated by FabA or 
FabZ to give trans-2-acetyl-ACP. In contrast to FabZ, FabA is a bifunctional 
enzyme and also catalyzes the isomerization of trans-2-acetyl-ACP to cis-3-
acetyl-ACP, essential for unsaturated fatty acid synthesis. FabA is only present 
in Gram-negative bacteria and it is believed that Gram-positive bacteria, which 
also produce unsaturated fatty acids, utilize other isomerases such as FabM and 
FabZ1 [18,19]. FabZ is the primary dehydratase in the FAS II pathway and 
simple inhibitors have been reported that show good in vitro activity for 
Helicobacter pylori [20]. However, the equilibrium that is catalyzed by FabZ 
lies to the side of the β-hydroxyacetyl-ACP complex and is not rate-limiting 
which makes it a somewhat less attractive target for new antibiotics. Inhibition 
of the reductase FabI in the last step of the FAS II pathway is considered to 
have more potential and is already targeted by triclosan, which is an 
antimicrobial agent that is widely used in a variety of consumer products [21]. 
Unfortunately, several key pathogenic bacteria, including Streptococcus 
pneumoniae, use FabK for this reduction step, which makes FabI less 
interesting for the development of broad-spectrum antibiotics [22].  
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Figure 2 Schematic representation of the bacterial type II fatty acid synthesis. 
Reproduced and modified from C. O. Rock et al. [11]. 
After the reduction step, the product can re-enter the catalytic cycle, but now the 
first step is performed by the elongation condensing enzymes FabB and FabF 
instead of the initiating ezyme FabH. Bacteria that express FabA typically 
utilize FabB for elongation of unsaturated fatty acids. However, in the absence 
of FabB, the second elongation enzyme FabF carries out the elongation of both 
saturated and unsaturated acyl-ACP's [23]. The crucial role of FabF and its 
ubiquitous presence in bacteria make this an attractive target for new 
antibacterials and several inhibitors for FabF have been reported. The first ones 
were cerulenin [24] and thiolactomycin [25] which displayed only weak 
antibiotic activity, precluding clinical use. More recently, platensimycin (1) and 
platencin (2) were discovered both proving potent inhibitors of FabF (IC50 = 
0.13 and 1.95 µg mL –1 respectively in S. aureus). Despite the lower affinity of 
platencin (2) for FabF, the overall in vivo efficacy of both compounds is 
comparable because platencin (2) also inhibits the previously discussed 
initiating enzyme FabH (IC50 = 3.91 µg mL –1 in S. aureus). 
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2 Results and Discussion 
As a result of the intriguing structure and valuable antibacterial properties, 
platensimycin (1) and platencin (2) became prime targets for synthetic chemists, 
resulting in a large variety of synthetic routes to these natural products [26]. It 
is, however, rather unlikely that the natural products platensimycin (1) and 
platencin (2) will find application as drugs due to their complex structures and, 
especially, their poor pharmacokinetic properties. Instead, as with many natural 
products, derivatives will have to be synthesized with improved 
pharmacokinetic properties and synthetic accessibility. While for platensimycin 
(1) several close analogues and a small library of simple analogues have been 
developed [27], it is quite surprising that for platencin (2) only two papers 
appeared with analogues in which the tricyclic core was modified. In 2009 
Snider et al. published a synthesis of nor-platencin (3), a close analogue of 
platencin which lacks the exo-methylene group (Figure 3) [28]. The researchers 
reasoned that the exo-methylene of platencin (2) might be superfluous as being 
merely a structural feature of the terpenoid precursor. In contrast to these 
expectations, nor-platencin (3) displayed a 4-16 fold lower activity than 
platencin (2) indicating that the exo-methylene significantly contributes to the 
activity of platencin.  
 
 
Figure 3 Structures of nor-platencin and iso-platencin. 
A second derivative, iso-platencin (4), was recently reported by Mulzer et al. 
who elaborated an intermediate of their synthesis of platencin to iso-platencin 
(4) [29]. The activity of iso-platencin (4) was comparable to that of platencin 
(2), but strikingly, for some bacteria, such as the key pathogen Enterococcus 
faecalis, all activity was lost. 
We recently reported a total synthesis of platencin (2), based on the efficient 
high-pressure-mediated Diels-Alder reaction of perillaldehyde (5) with the 
Danishefsky diene resulting in intermediate 6 in 82% yield as a single 
diastereisomer (Scheme 1) [30]. This intermediate was then converted into the 
platencin core 12 in 8 steps, thereby representing one of the shortest formal 
syntheses of this natural product. Interestingly, in an attempt to functionalize 
aldehyde 6 with TsOH in benzene at 80°C tricyclic diene 7 was formed in a 
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moderate yield of 48%. The unique structure of this diene was unambiguously 
confirmed by X-ray crystallographic analysis [31]. 
 
 
Scheme 1   High-pressure Diels-Alder reaction and unexpected cyclization of 
aldehyde 6. 
In Scheme 2, a plausible mechanism for the unexpected reactivity of aldehyde 6 
is shown, which proceeds via the Prins reaction. The proposed reaction pathway 
starts with protonation of aldehyde 6, followed by nucleophilic attack of the 
isopropenyl moiety. The intermediate tertiary cation 9 can eliminate in two 
ways, leading to either the allylic or homoallylic alcohol. However, molecular 
modelling (MM2) clearly indicated that allylic alcohol 10 is the thermodynamic 
product. In the next step, protonation and elimination resulted in the formation 
of the allylic cation 11, which can undergo elimination to diene 7. It is 
interesting to note that examples of seven-membered ring formation via a Prins 
cyclization are rather rare and to the best of our knowledge no examples exist 
that yield a cycloheptadiene.  
 
 
Scheme 2   Proposed mechanism for the Prins cyclization of diene 7. 
Clearly, diene 7 bears strong resemblance to the core structure of platencin (12, 
Scheme 2). An MM2 minimized overlap of both structures (not shown) 
revealed that the increased ring size of diene 7 does not alter the overall shape 
of the molecule compared to core structure 12 and only affects the orientation of 
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the exo-cyclic double bond. The strong similarity of core structures 7 and 12, 
and the exceptionally short synthesis of diene 7 sparked our interest in the 
antibiotic properties of a platencin analogue incorporating the latter moiety. 
Therefore, the Prins cyclization was optimized.  
Table 1 Optimization of the Prins cyclization step. 
 
Entry Catalyst Equiv T (°C) Additive Yield 7 (%)a Yield 13 (%)a 
1 TsOH 0.5 80 - 67 11 
2 TsOH 0.5 80 MgSO4 n.r.b n.r.b 
3 TsOH 0.1 Dean Stark - 54 12 
4 TsOH 0.5 80 hydroquinone 44 7 
5 CSA 0.5 80 - 44 8 
6c TfOH 1.5 0 °C to RT - 65 11 
a
 Isolated yield. b n.r. = no reaction. c Reaction performed in THF. 
 
This reaction is generally catalyzed by Brönsted and Lewis acids such as 
H2SO4, TsOH, BF3 and AlMe2Cl offering numerous possibilities for 
optimization [32]. In a preliminary screening of H2SO4, BF3⋅OEt2 and TsOH as 
catalysts in the Prins reaction of aldehyde 6, the latter acid clearly showed the 
best result according to TLC analysis and was selected for further optimization 
(Table 1). By shortening the reaction time to 30 min, the yield of diene 7 was 
increased to 67% (entry 1). Interestingly, the reaction with TsOH also gave rise 
to a side reaction, namely isomerization of the isopropenyl group leading to 
ketone 13. In theory, trapping the eliminated water in the Prins reaction should 
drive the equilibrium to diene 7 so that the reaction was also performed in the 
presence of MgSO4 (entry 2) and under Dean Stark conditions (entry 3). 
Surprisingly, the addition of MgSO4 inhibited the reaction and only little 
conversion was achieved upon prolonged heating. Under Dean Stark conditions, 
the reaction proceeded smoothly, however, without leading to a higher overall 
yield. Furthermore, the addition of hydroquinone to the reaction (entry 4) to 
suppress possible radical polymerization of diene 7 or changing the catalyst to 
the slightly milder acid CSA (entry 5) only decreased the yield. On the other 
hand, reaction of aldehyde 6 with the stronger acid TfOH in THF at RT (entry 
6) afforded the product in essentially the same yield as for entry 1, and thus 
represents a viable alternative to the thermal TsOH conditions. 
In order to synthezise the full platencin derivative, the methyl group and 
propionic acid linker had to be installed. In the synthesis of platensimycin (1) 
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this non-trivial challenge was first solved by Nicolaou, et al. [33]. Their 
strategy, which involved cross-metathesis with vinylboronic acid pinacol ester 
as the key step, was later also applied in their synthesis of platencin (2) [34]. 
Because of the structural similarity of diene 7 and the core structure of platencin 
(12), we decided to adopt the same strategy for the incorporation of the linker. 
The first step in this approach was α-alkylation of diene 7 with methyl iodide ( 
Scheme 3). Although the reaction proceeded in good yield, the presence of a 
small amount of the corresponding diastereoisomer (7:1) was somewhat 
unexpected. No diastereoisomer formation was reported for this step in the 
syntheses of platensimycin and platencin by Nicolaou et al. In the second step, 
ketone 14 was allylated with allyl iodide to give alkene 15 in 76% as an 
inseparable mixture of diastereoisomers (dr 10:3). With allyl bromide as the 
electrophile, also O-alkylation occurred to give enol ether 16 in 27% yield. 
Interestingly, upon GC analysis of the latter product, the thermal conditions 
efficiently promoted a Claisen rearrangement to give alkene 15 in the same dr 
of 10:3. 
 
 
Scheme 3   Incorporation of the propionic acid linker. 
The diastereomeric mixture of alkene 15 was reacted in the next step in a cross-
metathesis reaction with vinylboronic acid pinacol ester (17). Unsure about the 
effect of the diene moiety on the reaction, we were pleased to find that the 
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cross-metathesis proceeded well according to TLC analysis. However, after 
workup NMR analyses revealed a complex mixture of products. This can, at 
least in part, be attributed to the diastereomeric mixture used in the reaction and 
the formation of E- and Z-isomers. Since the products were inseparable by flash 
chromatography, the mixture was reacted further in the oxidation of the vinylic 
borane 18 with Me3NO to give aldehyde 19 in 35% yield over two steps 
(corrected for the dr of 10:3 of alkene 15). Aldehyde 19 was the only 
diastereoisomer that was isolated and subsequently reacted in a Pinnick 
oxidation to give carboxylic acid 20 in 91% yield.  
NH2
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Scheme 4   Completion of platencin derivative 23. 
The synthesis of the targeted platencin derivative 23, termed 
dehydrohomoplatencin, was completed using the methodology developed by 
Giannis and co-workers [35] and Nicolaou, et al. [34] Thus, aniline 21 was 
synthesized and subsequently coupled to carboxylic acid 20 with HATU and 
Et3N in DMF to yield amide 22 in 70% (Scheme 4). In the last step, the TMSE 
ester was deprotected by treatment with the fluoride donor TASF providing the 
completed derivative dehydrohomoplatencin (23) in 57% yield.  
With derivative 23 finally in hand, we determined its antibiotic profile and 
compared the results to the reported values of platensimycin (1) [36] and 
platencin (2) [37]. Much to our delight dehydrohomoplatencin (23) turned out 
to be virtually equipotent to natural products 1 and 2 and only for S. 
pneumoniae a striking loss of activity was observed (Table 2) [31]. 
Considering the lengthy sequence and moderate overall yield for the 
introduction of the C-3 linker in derivative 23, we became also interested in 
analogues incorporating linkers that are synthetically more readily accessible. In 
Scheme 5, the carbamate-linked derivative 26 is shown, which should in theory 
greatly facilitate the introduction of the linker. Moreover, replacement of the 
amide for a more electron-rich carbamate should also render the molecule more 
stable to hydrolysis.  
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Table 2 MIC values of derivatives 23 on multiresistant bacteria. 
Entry Organism Resistance MIC (µg/mL) of compounds 23 2 1 
1 S. aureus MSSA 1 - - 
2 S. aureus MRSA 1 1 0.5 
3 S. aureus er. R,a cl. Sb 1 - - 
4 S. aureus MSSA 0.5 0.5 0.5 
5 S. aureus macrolid R 1 1 0.5 
6 E. faecalis - 2 2 1 
7 E. faecalis VRE 2 - - 
8 E. faecium - 0.12 - - 
9 E. faecium VRE 0.12 <0.06 0.1 
10 CNS - 0.25 - - 
11 CNS MRSE 0.12 - - 
12 S. pneumoniae - >16 4 1 
13 S. pneumoniae macrolid R >16 - - 
14 S. pneumoniae penicillin R >16 - - 
 
 
Thus, alcohol 24 was synthesized by treatment of ketone 14 with LDA and 
formaldehyde in 50% yield as an easily separable mixture of diastereoisomers 
and 24% of recovered starting material. The relative configuration of both 
alcohols was readily assigned with NOESY. The challenging intermolecular 
coupling of the desired diastereoisomer of 24 with the hindered aniline 21 was 
achieved in a one-pot procedure involving carbonyldiimidazole (CDI) and 
DMAP in 33%. Finally, deprotection was effected with TASF to give the 
carbamate derivative 26 in 47% yield. Although the overall yield over the three 
steps is low, sufficient material was obtained to determine the antibiotic profile 
of derivative 26. In contrast to our expectations, compound 26 did not show any 
antibiotic activity for MRSA or VREF and therefore no optimization of the 
synthetic pathway was performed.  
 
 
Scheme 5    Synthesis of carbamate derivative 26. 
 
Another derivative that was synthesized is triazole 27 (Scheme 6). In this 
analogue the amide is substituted for a triazole and the methyl group at the α-
a
 er. R. = erythromycin R. b cl. S. = clindamycin S  
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position of the ketone is absent. Again, these modifications were synthetically 
driven and aimed to considerably simplify the synthesis. We also realized that 
even though triazoles are bioisosteres of amides, the hydrogen bond donor 
interaction that the amide group in platencin has with the enzyme cannot be 
mimicked by the triazole, which might decrease the activity of the triazole 
derivative. Triazole 27 can be assembled in two steps via a 1,3-dipolar 
cycloaddition of azide 28 with alkyne 29 and subsequent TASF deprotection. A 
considerable advantage of the absence of the methyl group in alkyne 29 is that, 
in the case of diastereoisomer formation in the alkylation step, epimerization to 
the thermodynamic product should be possible. 
 
Scheme 6   Retrosynthesis of triazole derivative 27. 
The synthesis of azide 28 commenced with nitration of resorcinol, as developed 
by Giannis, et al. (Scheme 7) [35]. Treatment of resorcinol 30 with nitric acid 
and acetic anhydride in acetic acid yielded nitroresorcinol 31 in 35% together 
with 23% of regioisomer 32. Subsequent MOM protection of both phenol 
groups and reduction of the nitro group with H2 and Pd/C afforded aniline 34 in 
good yield. The scalability and speed of this approach easily outweighs the low 
yield of the first step and made this the preferred synthetic pathway to aniline 
34. In the last step, the azide was introduced via diazotransfer with triflyl azide 
to give azide 28 in low yield. No optimization was carried out since sufficient 
material was obtained to complete the synthesis of the derivative. 
 
 
Scheme 7   Synthesis of azide 28. 
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The synthesis of the second cycloaddition partner was realized by alkylation of 
ketone 7 with 3-bromo-1-(trimethylsilyl)-1-propyne, which, after deprotection 
with K2CO3, yielded alkyne 29 in 74% yield over two steps b.r.s.m. (Scheme 8). 
Notably, the product was obtained as a single diastereoisomer and no additional 
epimerization step was required. According to the large coupling constant of J = 
12.8 Hz for the α-proton, the propargyl group must be in the equatorial position. 
In the final stage of the synthesis, alkyne 29 was reacted with azide 28 in a 
copper-catalyzed 1,3-dipolar cycloaddition reaction. Simple copper wire, 
routinely used for this reaction in our group, failed to give any reaction and the 
addition of copper iodide was required for the reaction to proceed. In the next 
step, hydrolysis of the methyl ester, followed by deprotection of both MOM 
ethers afforded derivative 27. The low yield was mainly caused by repetitive 
chromatography which was required to remove all impurities. It seemed that 
derivative 27, and also the other platencin derivatives synthesized in this 
project, partially decomposed on silica gel as indicated by the color change of 
the silica gel after chromatography. The fact that researchers from Merck lost 
all the isolated platensimycin upon drying the extract with MgSO4 instead of 
Na2SO4, further supports the hypothesis that derivative 27 may bind strongly to, 
or decompose on, polar surfaces [38]. 
 
 
Scheme 8    Synthesis of triazole derivative 27. 
Disappointingly, derivative 27 also showed no antibiotic activity towards 
MRSA and VREF. The lack of activity of derivatives 26 and 27 might be 
explained by considering the three dimensional structure of platencin (2) in the 
active site of FabF (Figure 4) in E. coli [39]. From this figure it becomes clear 
that the linker is twisted 63° out of the plane of the amide, something which is 
unfavorable in the case of the carbamate linker due to the hindered rotation 
around the oxygen-carbon bond. For triazole derivative 78, this twisted 
conformation is structurally simply impossible. Consequently, the aliphatic and 
aromatic parts of derivatives 26 and 27 have a completely different orientation 
and cannot bind in the same way as platencin (2) in the active site of the 
enzyme.  
 Synthesis and Biological Activity of Novel Platencin Derivatives 107 
 
 
Figure 4 Conformation of platencin (2) in the active site of FabF in E. coli. 
3 Conclusions 
In conclusion, we have developed a short enantiopure synthesis of the platencin 
derivative dehydrohomoplatencin. The novel ketolide portion of 
dehydrohomoplatencin was accessed in only two steps with high atom 
efficiency and includes an unprecedented Prins cyclization reaction. By this 
exceedingly simple protocol we were able to routinely synthesize the ketolide 
structure on multigram-scale. The introduction of the aromatic part was 
performed in moderate overall yield. The completed derivative, 
dehydrohomoplatencin, proved virtually equipotent to platencin and only lacked 
activity against S. pneumoniae. Substitution of the amide functionality in the 
linker of dehydrohomoplatencin by a carbamate or triazole group resulted in a 
complete loss of activity. These findings can be rationalized by inherent 
conformational restrictions for the new linkers as compared to the amide linker 
in platencin. 
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